Furong Biotech, established in 2019, is a prominent player in the biotechnology and pharmaceutical industries. The company, headquartered in Suzhou with centers in Shanghai, harnesses synthetic immunology for the creation of next-generation immunotherapy protein drugs, focusing on innovative macromolecular drugs such as cytokines.
Its slogan, "Synthetic immunology for next-generation immunotherapy protein drugs," emphasizes its commitment to pioneering advancements in healthcare. Furong Biotech has developed an integrated synthetic immune technology system that underpins its research and development efforts, setting it apart in the market.
Recently, Furong Biotech secured a significant CNY120.00M Early VC investment on 01 May 2026, attracting attention from notable investors like Changshu Guofa Venture Capital and Fudan Venture Capital, an indicator of confidence in its technological capabilities and growth potential.
